- US-listed companies
- Royalty Pharma plc
- Income statement
Royalty Pharma plc【RPRX】Income statement
Market cap
$23.4B
P/E ratio
| 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 2,122 | 2,289 | 2,237 | 2,355 | 2,264 |
| Revenue growth (%) | - | ||||
| Research & development | 26 | 200 | 177 | 52 | 2 |
| Operating margin (%) | |||||
| Operating income | 1,595 | 1,431 | 307 | 1,492 | 1,292 |
| Operating expenses | 527 | 859 | 1,930 | 862 | 971 |
| Income before tax | 1,702 | 1,241 | 230 | 1,700 | 1,331 |
| Pretax margin (%) | 80.2 | 54.2 | 10.3 | 72.2 | 58.8 |
| Net income | 1,702 | 1,241 | 230 | 1,700 | 1,331 |
| Net income margin (%) | |||||
| Earnings per share | 1.32 | 1.49 | 0.1 | 2.54 | 1.92 |
| Diluted EPS | 1.32 | 1.49 | 0.1 | 2.53 | 1.91 |
| Dividend payout ratio (%) | |||||
| Dividend per share | 0.15 | 0.68 | 0.76 | 0.8 | 0.84 |